pyrazines has been researched along with Hepatitis C in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Akagi, Y; Fujioka, S; Inaba, T; Ito, S; Kinoshita, W; Komoda, Y; Kondo, K; Maeda, K; Nakamura, H; Okuda, S; Tamatani, Y; Terui, T; Ukaji, Y | 1 |
Abdurakhmanov, E; Belfrage, AK; Brandt, P; Danielson, UH; Gising, J; Kerblom, E; Neyts, J; Oshalim, A; Sandström, A; Skogh, A | 1 |
Birkenbach, M; Constantinescu, S; Daller, JA; Gillespie, A; Karachristos, A; Lee, I; Leech, S; Sifontis, NM; Silva, P; Swami, A | 1 |
Cho, SH; Choi, JY; Chon, CY; Han, JY; Jang, JJ; Jang, JW; Kim, SG; Kim, YM; Lee, DH; Lee, YS; Um, SH; Yu, E | 1 |
Matsumori, A | 1 |
1 review(s) available for pyrazines and Hepatitis C
Article | Year |
---|---|
Cytokines in myocarditis and cardiomyopathies.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Cytokines; Heart Injuries; Hepatitis C; Humans; Mice; Mice, Mutant Strains; Myocarditis; Pyrazines; Quinolines | 1996 |
1 trial(s) available for pyrazines and Hepatitis C
Article | Year |
---|---|
Oltipraz therapy in patients with liver fibrosis or cirrhosis: a randomized, double-blind, placebo-controlled phase II trial.
Topics: Adult; Anticarcinogenic Agents; Biomarkers; Biopsy; Collagen; Double-Blind Method; Female; Hepatitis B; Hepatitis C; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrazines; Thiones; Thiophenes; Transforming Growth Factor beta1 | 2011 |
3 other study(ies) available for pyrazines and Hepatitis C
Article | Year |
---|---|
Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
Topics: Administration, Oral; Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Mutation; Pargyline; Pyrazines; Structure-Activity Relationship; Viral Nonstructural Proteins; Virus Replication | 2020 |
Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Molecular Docking Simulation; Point Mutation; Protease Inhibitors; Pyrazines; Viral Nonstructural Proteins | 2016 |
Bortezomib as therapy for mixed humoral and cellular rejection: should it be first line?
Topics: B-Lymphocytes; Boronic Acids; Bortezomib; Creatinine; Follow-Up Studies; Graft Rejection; Hepatitis C; Humans; Immunity, Cellular; Immunity, Humoral; Immunoglobulins, Intravenous; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Protease Inhibitors; Pyrazines; T-Lymphocytes | 2009 |